Skip to main content

Goldberg Itzhak's Form 4 filing

Elicio Therapeutics, Inc. (ELTX) · filed Nov 17, 2021

Accession no.
0001601485-21-000075
Filed
Nov 17, 2021
Trade date
Jun 24-Nov 16, 2021
Filing delay
146 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions. Open-market sales total $629.0K. It was filed 146 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Goldberg ItzhakCIK 0001607858Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 24, 2021Common StockFTax withholdingDisposed−47,410$13.78−$653,309.82,020,068Direct
Nov 15, 2021Common StockSSaleDisposed−111,505$4.17F3−$464,975.851,908,563Direct
Nov 16, 2021Common StockSSaleDisposed−38,495$4.26F4−$163,988.71,870,068Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.48 inclusive.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.21 to $4.38 inclusive.

Referenced by the price of 1 transaction in Table I.

Remarks

Executive Chairman and Chief Scientific Officer

Read the full filing on SEC EDGAR (opens in a new tab)